In contrast, approximately 80% of patients with ALL after CD19 CAR-T cell therapy had CR after CD22 CAR-T cell therapy, which was not different from patients who did not receive CD19 CAR-T cell therapy (20, 39). Here, CD19 is linked to acute lymphoblastic leukemia.